Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease
Abstract Background The need for preventive therapies that interrupt the progression of Alzheimer’s disease (AD) before the onset of symptoms or when symptoms are emerging is urgent and has spurred the ongoing development of disease-modifying therapies (DMTs) in preclinical and early AD (mild cognit...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BMC
2022-04-01
|
| Seri Bilgileri: | Alzheimer’s Research & Therapy |
| Konular: | |
| Online Erişim: | https://doi.org/10.1186/s13195-022-00984-y |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|